1. Introduction {#sec1}
===============

Psoriasis is an immune-mediated cutaneous disease with an estimated prevalence of approximately 2% in the European and North American population \[[@B1], [@B2]\]. The most common clinical presentation of psoriasis, namely, psoriasis vulgaris (PV), is defined by multiple erythematosquamous plaques, histologically characterized by (1) epidermal acanthosis, hyperkeratosis, and parakeratosis; (2) dilated capillary network in the papillary dermis; (3) a mixed inflammatory infiltrate including polymorphonuclear cells, as well as intraepidermal collections of neutrophils \[[@B3]\]. Epidermal clusters of neutrophils have been given eponymous names such as Munro\'s microabscesses and Kogoj pustules \[[@B3]\]. Various evidences deriving from genetic studies, adoptive transfer models, and molecular evaluation of human samples point to a key pathogenetic role for T helper-1 (Th1)/Th17 cells and related cytokines (including TNF-alpha, IL-17, and IL-22), as well as for myeloid cell-derived cytokines such as IL-12 and IL-23 \[[@B1], [@B2], [@B4]--[@B8]\].

Pustular psoriasis (PP) is a clinicopathological variant of psoriasis distinguished by the following features: (1) clinically, presence of pustules on variably erythematous skin; (2) histopathologically, predominance of intraepidermal collections of neutrophils \[[@B9]--[@B11]\]. Any bioptic sample presenting the histologic picture of PP should always undergo further investigations to rule out the eventuality of superficial dermatophytosis or*Candida albicans* infection, whose histopathologic features are often indistinguishable from those of PP \[[@B12], [@B13]\].

PP has been classified into generalized and localized forms \[[@B14]\]. Generalized PP is a life-threatening, systemic inflammatory condition characterized by repeated attacks of diffuse, erythematous, pustular rash associated with high-grade fever, general malaise, and frequent extracutaneous organ involvement; possible laboratory testing abnormalities include leukocytosis with left shift, increased erythrocyte sedimentation rate (ESR), or increased C-reactive protein (CRP) \[[@B14], [@B15]\]. Acute flare-ups of generalized PP may be triggered by pregnancy status, infection, or exposure to drugs \[[@B15]\]. Though generalized PP formally belongs to the psoriasis spectrum because of its frequent clinical association with PV and multiple similarities in molecular pathogenesis, it is debated whether it may represent a distinct clinicopathological entity \[[@B16], [@B17]\]. Another controversy is related to the classification of generalized PP alone or accompanied by PV as distinct subtypes with different etiologies \[[@B17]\]. Likewise, localized PP, which is often limited to palms and soles (i.e., palmoplantar pustulosis), has been regarded by several authors as a separate entity rather than a clinical variant of psoriasis \[[@B17], [@B18]\]. However, a close relationship between localized PP and PV is likely suggested by lack of significant epidemiologic differences, frequent coexistence in the same patients, and largely shared genetic background \[[@B18]\].

Conventional first-line therapies for PP include topical corticosteroids, phototherapy, acitretin, cyclosporine, and methotrexate \[[@B14], [@B16]\]. Because the use of therapeutics is often hampered by low efficacy and/or adverse effect profile, a need to develop novel therapeutic approaches for PP is arising \[[@B14]\]. Infliximab is actually recognized by many experts as a first-line treatment option for PP, especially in severe cases \[[@B14], [@B19], [@B20]\]. Nonetheless, paradoxical TNF-alpha inhibitor--induced PP is a newly occurrence, whose pathogenic mechanism is still relatively unclear \[[@B21], [@B22]\].

The pathogenic process underlining PP development is only partially shared with PV \[[@B16], [@B17]\]. The efficacy of TNF-alpha inhibitors in most patients with PP or PV points to a crucial role of TNF-alpha in their pathogenesis \[[@B14]\]. In addition to TNF-alpha, alternative signaling pathways relevant to PP include those mediated by IL-17 and the IL-1/IL-36 family \[[@B17], [@B23]--[@B25]\]. Furthermore, recent evidence seems to indicate IL-6 as a new druggable target for PP \[[@B23]\].

2. Psoriasis Pathogenesis: Current Concepts {#sec2}
===========================================

2.1. The IL-23/Th17 Axis in the Pathogenesis of Psoriasis {#sec2.1}
---------------------------------------------------------

A distinct lineage of IL-23-responsive CD4+ T cells secreting IL-17A and IL-17F and expressing the lineage-specific transcription factor RORC has been recently identified as Th17 cells \[[@B1], [@B5], [@B26]--[@B28]\]. Additional effector cytokines produced by Th17 cells include IL-21 and IL-22, as well as other non-Th17-specific cytokines, such as IL-6 \[[@B29]--[@B31]\]. Cytokine requirements for inducing Th17 differentiation are similar in mice and humans \[[@B26], [@B32]\]. Naive CD4+ T-cell activation in the presence of both TGF-beta and IL-6 is key to priming the initial differentiation into Th17 cells \[[@B2], [@B27]\]. TGF-beta also exerts an indirect action through suppression of T-bet-dependent Th1 differentiation \[[@B2], [@B26]\]. IL-6-dependent STAT3 activation plays an essential role in Th17 differentiation by initially inducing the transcription of*RORC*,*IL17*, and*IL23R* genes and later promoting the expansion of differentiated and memory Th17 cells \[[@B26], [@B32]\]. However, TGF-beta and IL-6-driven Th17 cells are weakly functional without further exposure to IL-23; the latter cytokine is crucial for differentiation into effector cells, lineage stabilization, and full maturation to inflammatory Th17 cells \[[@B2], [@B5], [@B27], [@B28], [@B33]\].

Psoriasis skin lesions are the result of complex interactions between dendritic cells (DCs), keratinocytes, and Th1/Th17 lymphocytes \[[@B30], [@B34], [@B35]\]. Recent pathogenic models of psoriasis emphasized the role of IL-23/Th17 axis \[[@B1], [@B2], [@B5], [@B36]\]. IL-23 production by inflammatory DCs and activated keratinocytes stimulates Th17 cells within the dermis to release proinflammatory mediators such as IL-17 and IL-22 that, in turn, activate resident tissue cells, particularly keratinocytes \[[@B33], [@B35]\]. Psoriatic plaques harbor higher levels of IL-23p19 and IL-12/23p40 than those of IL-12p35 \[[@B1], [@B27]\]; polymorphisms in*IL12/23p40* and*IL23R* genes are associated with increased risk of developing psoriasis, and injection of recombinant IL-23 into healthy skin results in inflammatory changes with histologic features of psoriasis \[[@B5], [@B30]\]. According to this evidence, the pathogenic relevance of IL-23 has been also confirmed by the high efficacy of both anti-IL-12/IL-23p40 monoclonal antibodies (i.e., ustekinumab) and IL-23p19 neutralizing agents (i.e., tildrakizumab) \[[@B8], [@B27], [@B33], [@B37], [@B38]\].

IL-17A (simply known as IL-17) belongs to the IL-17 cytokine family, which includes six members (from IL-17A to IL-17F) \[[@B1], [@B2]\]. IL-17A shows similar pleiotropic effects acting on a wide range of nonimmune cells, resulting in the induction of different proinflammatory cytokines, chemokines, antimicrobial peptides, nitric oxide, and matrix metalloproteinases \[[@B1], [@B2], [@B30], [@B34]\]. IL-17 is able to induce IL-6, IL-8, and CXCL5 in human skin keratinocytes, indirectly promoting the differentiation, activation, and migration of neutrophils \[[@B5], [@B34], [@B35]\]. Bioptic samples from PV plaques show elevated levels of IL-17 in parallel with increased expression of IL-23 and IL-22, while serum levels of IL-17 are correlated to psoriasis severity \[[@B2], [@B6], [@B30], [@B39]\]. IL-22 is another key downstream cytokine in the IL-23/Th17 axis, being upregulated in psoriatic skin as compared to normal skin \[[@B5], [@B29], [@B40], [@B41]\]; IL-22 mediates keratinocyte hyperplasia via STAT3 activation, leading to psoriasiform hyperplasia. In the absence of IL-22, severity of both IL-23-mediated and imiquimod-induced psoriasis-like dermatitis in corresponding mouse models is markedly reduced \[[@B40], [@B42], [@B43]\].

A significant increase in IL-17 expression has been detected in lesional skin of PP, despite the absence of any significant increase in IL-12/IL-23 levels \[[@B44]\]; this is strikingly different from PV, where increased IL-17 levels are typically mirrored by analogous changes in IL-12/IL-23 expression \[[@B7], [@B37], [@B43]\]. Accordingly, conventional Th17 may not be the main driver for increased IL-17 expression in PP, with neutrophils being a possible, alternative source of IL-17 \[[@B23], [@B44]\]. Indeed, the anti-IL-23 agent ustekinumab appears to be significantly less effective in the treatment of PP than that of PV \[[@B44]--[@B46]\]. Of note, the immunopathology of two well-known histologic mimics of PP, that is, superficial dermatophytosis and mucocutaneous*Candida albicans* infection, relies heavily on the production of IL-17, as suggested by mouse models and rare human patients with loss-of-function defects in the*IL17* gene \[[@B47]--[@B50]\]. It is now clear that IL-17-dependent recruitment of neutrophils and secretion of antimicrobial peptides are crucial for cutaneous protection against dermatophytic infections and*Candida albicans* \[[@B47], [@B49]--[@B51]\]. Importantly, the cellular sources of IL-17 production in this setting are not limited to conventional CD4+T cells, as several components of the innate immunity (gamma/delta T cells, mast cells, and neutrophils) appear to be capable of immediate IL-17 secretion prior to the contribution of IL-23-dependent Th17 adaptive immunity \[[@B42], [@B48]--[@B52]\].

2.2. IL-36 and Pustular Psoriasis {#sec2.2}
---------------------------------

Pathogenic*IL36RN* gene mutations have been identified in familiar and sporadic cases of PP, either generalized or localized \[[@B25], [@B53], [@B54]\];*IL36RN* encodes the IL-36 receptor antagonist (IL-36Ra), a soluble mediator that antagonizes the proinflammatory activity of IL-36 cytokines (IL-36-alpha, IL-36-beta, and IL-36-gamma) through binding IL-36R (IL-1RL2) and inhibiting IL-36-dependent activation of NF-kappaB signaling \[[@B25], [@B55]--[@B57]\].

Several authors have detected elevation of keratinocyte-derived IL-36 cytokines levels in psoriatic lesional skin, as a result of keratinocyte stimulation by IL-17, IL-22, and TNF-alpha \[[@B58]--[@B60]\]. Primary epidermal IL-36 overexpression in transgenic mouse models results in PV-like phenotype histopathologically characterized by acanthosis, hyperkeratosis, and mixed inflammatory infiltration with predominance of neutrophils \[[@B55], [@B59]\]; further crossing with*IL36RN*-knockout strain augments IL-36 signaling leading to increased neutrophil infiltration and a histopathological picture more akin to classic PP \[[@B25], [@B55], [@B61]\]. Furthermore, loss of IL-36R signaling successfully counteracts development of imiquimod-induced psoriasiform dermatitis, pointing to a crucial role of IL-36 ligands in the proinflammatory activity of the IL-23/Th17 axis \[[@B61], [@B62]\]. Indeed, IL-36R signaling is relevant for the expansion of IL-17-producing T helper cells \[[@B25], [@B55]\].

IL-36 cytokines may exert a direct effect on immune cells \[[@B55]\]; activation of IL-36R, which is expressed constitutively on DCs, CD4+ T cells, and macrophages, promotes maturation of monocyte-derived DCs and induction of several cytokines, including IL-1, IL-6, IL-23, TNF-alpha, and IFN-gamma \[[@B59], [@B61], [@B63]\]. In addition, keratinocytes in psoriasis as well as synoviocytes in RA are capable of responding to direct IL-36 ligands stimulation with production of IL-6, IL-8, and antimicrobial peptides, which cooperate with IL-17A and TNF-alpha promoting neutrophil activation and migration \[[@B11], [@B54], [@B56], [@B60]\].

Thus, IL-36 ligands not only act as effector cytokines of the IL23/Th17 axis, but also induce several proinflammatory mediators (including IL-6, IL-8, and IL-23) that reinforce the Th17-driven inflammatory milieu \[[@B25], [@B59], [@B60], [@B63]\]. The cross-talk between IL-36 ligands and Th17 mediators establishes a positive feedback loop involving keratinocytes, DCs, macrophages, and Th17 \[[@B60], [@B61]\]; as a consequence, activation of T cells is enhanced, recruitment of immune cells in psoriatic lesions is augmented, and the IL-23/Th17 axis is reinforced \[[@B55], [@B60]\]. In keeping, elevation of IL-36R ligands in psoriatic plaques is closely correlated with increased levels of TNF-alpha, IL-17, and IL-22, confirming the existence of a proinflammatory, self-reinforcing gene expression loop \[[@B56], [@B59]\].

Pathogenetic*IL36RN* mutations associated with PP abolish the antagonistic effect of IL-36Ra, enhancing the IL-36-dependent production of IL-1, IL-6, and IL-8 \[[@B25], [@B54]\]. Indeed, patients with*IL36RN*-dependent genetic predisposition to PP have been treated effectively with anakinra, an IL-1 antagonist \[[@B64]\]. Nonetheless, so far no specific data regarding effectiveness of IL-6 inhibitors in*IL36RN*-dependent PP are available. Overall, recessive*IL36RN* mutations are associated with increased risk of PP alone, but not PV \[[@B57], [@B65]--[@B67]\]; both phenotypic variance and incomplete penetrance have been observed, supporting the notion that*IL36RN* mutations are able to induce manifest disease only in the presence of specific environmental factors and/or further genetic defects at a second disease locus \[[@B25], [@B53], [@B65]\]. All genetic follow-up studies of PP patients have found evidence of genetic heterogeneity, proving that*IL36RN* mutations account for only a minority of sporadic PP cases \[[@B25], [@B57], [@B66]\].

3. IL-6 Signaling and Pustular Psoriasis {#sec3}
========================================

3.1. IL-6 Signaling and Selective IL-6 Inhibition {#sec3.1}
-------------------------------------------------

IL-6, a pleiotropic, proinflammatory cytokine, is the archetypal member of the gp130-related cytokine family, which also includes IL-11, IL-27, OSM, CNTF, CT-1, LIF, and CLC \[[@B68], [@B69]\]. IL-6 exerts its activity through interaction with a receptor complex composed of the nonsignaling alpha subunit IL-6R (CD126) and the common, ubiquitously expressed, beta subunit gp130 (CD130), resulting in immediate activation of receptor-associated kinases (JAK1/JAK2 and TYK2) and subsequent regulation of STAT1/STAT3 and SHP2-MAPK signaling pathways ([Figure 1](#fig1){ref-type="fig"}) \[[@B68], [@B70], [@B71]\]. The IL-6R subunit functions*in vivo* as both a conventional membrane-bound receptor, expressed on the surface of hepatocytes and certain inflammatory cells, and a soluble form (sIL-6R) which forms active IL-6/sIL-6R complexes (IL-6 transsignaling) \[[@B72], [@B73]\]; this property is unique to IL-6 among currently known cytokines \[[@B68]--[@B70]\].

In addition to being a major stimulus for the synthesis of acute-phase proteins, IL-6 promotes differentiation of B cells into mature plasma cells as well as T-cell differentiation and activation \[[@B69], [@B72]\]. Importantly, recent evidence demonstrated that IL-6 exerts a positive influence in initiating Th17 cell development, whereas it inhibits TGF-beta-dependent differentiation of regulatory T cells \[[@B32], [@B74]\]. IL-6 is also a downstream target gene of IL-17 signaling in nonimmune cells such as keratinocytes and fibroblasts \[[@B35], [@B72], [@B75]\]; this positive IL-6/IL-17 loop plays a key role in proinflammatory interactions between the immune system and nonimmune tissues \[[@B32], [@B76]\]. Additionally, IL-6 exerts a significant influence on myeloid precursor cells and circulating neutrophils \[[@B69], [@B77]--[@B79]\]: IL-6 promotes differentiation from myeloid progenitors to neutrophils as well as neutrophilia \[[@B80]\]. Furthermore, IL-6 secretion results in secondary production of chemokines such as IL-8 and MCP-1 by mononuclear cells/macrophages as well as expression of ICAM-1 and other adhesion molecules on endothelial cells, leading to enhanced neutrophil migration \[[@B75], [@B77], [@B79]\]. Last, mature neutrophils respond to IL-6 via membrane-bound IL-6R, releasing proinflammatory cytokines such as IL-23 and IL-17 and establishing a Th17-polarizing positive feedback loop \[[@B32], [@B76]\].

Transgenic*IL6*-KO mouse models are characterized by a unique resistance to several inflammatory conditions such as experimental autoimmune arthritis or encephalomyelitis \[[@B69], [@B70]\]; accordingly, IL-6 plays a central role in the pathogenesis of several autoimmune diseases, including rheumatoid arthritis, juvenile idiopathic arthritis, adult onset Still\'s disease, systemic lupus erythematosus, Takayasu\'s arteritis, and inflammatory bowel disease \[[@B69], [@B72], [@B75]\]. As a consequence, IL-6 has gained attention as an attractive therapeutic target for autoimmunity, leading to the clinical development of anti-IL-6R agents such as tocilizumab \[[@B72], [@B81]\]. Tocilizumab is a monoclonal antibody which globally blocks IL-6 biologic activity by antagonizing both conventional membrane-bound signaling and sIL-6/IL-6R transsignaling, resulting in a strong inhibition of IL-6-dependent STAT1/STAT3 activation \[[@B70]\]. Tocilizumab is an established therapeutic option for rheumatoid arthritis and juvenile idiopathic arthritis, although the field of tocilizumab-responsive autoimmune conditions is still expanding \[[@B68], [@B69], [@B81], [@B82]\].

3.2. IL-6 in the Pathogenesis of Psoriasis {#sec3.2}
------------------------------------------

IL-6 has long been associated with psoriasis pathogenesis \[[@B83]--[@B85]\]. In addition to known psoriasis susceptibility loci encoding proteins engaged in the TNF-alpha, IL-23, and IL-17 signaling pathways (including*HLA-Cw6*,*IL23R*,*IL12B*,*IL23A*, and*TNFAIP3* genes),*IL6* and*STAT3* polymorphisms have been linked with hereditary predisposition of developing psoriasis and response to TNF-alpha inhibitors \[[@B33], [@B86]--[@B89]\]. Increased skin and serum IL-6 levels are a feature of psoriasis \[[@B39], [@B84], [@B90]\]. Serum levels of IL-6 are regarded as a marker of the inflammatory activity in psoriasis as well as an indicator of treatment response \[[@B4], [@B39], [@B84], [@B85]\]; a positive correlation between IL-6 serum levels and clinical severity of PV before treatment has been described \[[@B4], [@B90]\]. Additionally, serum IL-6 levels have been reported to decrease after effective treatment with methotrexate or UVB phototherapy \[[@B91], [@B92]\]. Furthermore, the likelihood of a positive Köebner reaction has been reported to correlate with higher proportions of IL-6+ mast cells and IL-6R+ cells in the dermis \[[@B93]\].

IL-6 is produced by a wide range of cell types in psoriatic plaques (including keratinocytes, fibroblasts, endothelial cells, DCs, and macrophages) in response to several stimuli, such as IL-1, TNF-alpha, IL-17, and IL-36 ([Figure 2](#fig2){ref-type="fig"}) \[[@B84], [@B94]--[@B96]\]. Human keratinocytes stimulated by IL-17 or IL-36 may serve as a significant source of IL-6 \[[@B35], [@B76], [@B85], [@B94]\]; furthermore, a population of dermal slan-DCs has been recently identified as proinflammatory myeloid DCs in psoriatic skin lesions, which is capable of producing significant levels of IL-6 together with TNF-alpha, IL-1b, IL-23p19, and IL-12p70, all of which have proven crucial for the polarization of pathogenic Th17 and Th1 cells \[[@B95]\]. Importantly, the synergistic effects of IL-17 and TNF-alpha are capable of further upregulating IL-6 in psoriasis lesional skin; hence, selective targeting of either IL-17 or TNF-alpha exerts additional beneficial effects by indirectly reducing IL-6 levels \[[@B32], [@B35], [@B94], [@B96]\].

The key pathogenetic role of IL-6 signaling pathway in psoriasis is supported by evidence deriving from mouse models of psoriasis-like skin disease relying on constitutive activation of STAT3 in keratinocytes \[[@B71], [@B97], [@B98]\]. Increased activation of STAT3 (pSTAT3) has been detected in lesional skin of psoriatic patients \[[@B98]\]; several cytokines upregulated in psoriasis, including IL-6, IL-20, and IL-22, signal through STAT3 activation \[[@B71], [@B98]\]. STAT3 phosphorylation influences the expression of genes controlling keratinocyte survival and proliferation through interactions with other transcription factors such as NF-kappaB \[[@B96], [@B99]\]. STAT3 activation has a key role in the psoriasis-associated IL-23 signaling cascade \[[@B71], [@B97], [@B99]\]. Accordingly, JAK inhibition is being assessed as a novel therapeutic strategy for treatment of psoriasis. Importantly, IL-6 produced by DCs, macrophages, T cells, and keratinocytes further augments the IL-6-rich microenvironment in psoriatic plaque, resulting in the robust induction of pSTAT3 in effector and memory Th17 cells \[[@B76]\]. Persistent pSTAT3 signaling in T cells is required for initial Th17 differentiation and promotion of Th17 cytokines production, unleashes unrestrained activation of effector T cells, and prevents suppressive activity of T regulatory cells \[[@B76]\]. Additionally, IL-6-mediated pSTAT3 signaling is capable of enhancing keratinocyte growth and proliferation, promoting psoriasis epidermal hyperplasia \[[@B96], [@B98]\]; IL-6 signaling on keratinocytes also induces chemoattractant proteins via AP-1 downstream activation \[[@B97]\].

IL-6 is a key mediator of IL-23/Th17-driven cutaneous inflammation \[[@B37], [@B94]\]. IL-23-induced dermal inflammation in psoriasis mouse models relies on T cells and IL-6 \[[@B96]\]. In IL-6-deficient mice, intradermal injections of IL-23 lead to increased IL-22 production compared with WT mice, but this response is not sufficient for effective dermal inflammation and epidermal hyperplasia \[[@B96]\]. This finding seems to be secondary to insufficient expression of IL-22R1A in the absence of IL-6. The increased level of IL-6 in the skin of imiquimod-treated*lL17RA*-del mice compared with treated WT skin confirms the role of IL-6 in disease development in the absence of IL-17 signaling \[[@B41]\]. Accordingly, imiquimod is thought to indirectly activate the preexisting IL-17-producing T cells, which are capable of secreting other cytokines such as IL-6 that drive development of psoriasiform dermatitis independent of IL-17 \[[@B41], [@B43]\].

3.3. IL-6 and Pustular Psoriasis {#sec3.3}
--------------------------------

Recent evidence points to an unexpected, central role of IL-6 in driving the abnormal recruitment of neutrophils into lesional skin of PP \[[@B23]\]; accordingly, IL-6 would be the key downstream mediator acting together with IL-17 to induce excessive skin infiltration by neutrophils resulting in intraepidermal pustules typical of PP ([Figure 2](#fig2){ref-type="fig"}) \[[@B23]\]. Importantly, IL-6 could be a novel, attractive target for the treatment of PP, in the light of the current availability of biologic agents safely and effectively antagonizing IL-6.

IL-6 has been long known to favor neutrophil differentiation and activation both*in vivo* and*in vitro*\[[@B79], [@B80]\]. Positive correlations have been recorded between IL-6 serum levels and clinical severity of PP, as well as associated leukocytosis, ESR, and CRP levels \[[@B100], [@B101]\]. Clinical improvement of PP following tonsillectomy has been paralleled by reduction of serum IL-6 levels \[[@B102]\]; in keeping,*in vitro* exposure of tonsillar mononuclear cells to streptococcal antigens resulted in increased production of IL-6 \[[@B91], [@B103]\].

The K14-*IL17A*-ind/+ transgenic mouse represents an animal model of psoriasiform dermatitis characterized by deregulated, persistent overexpression of IL-17A in epidermal keratinocytes leading to prominent development of intraepidermal neutrophil microabscesses in addition to dermal T-cell infiltration, hyperkeratosis, and parakeratosis \[[@B23]\]. The immunopathogenesis observed in the K14-*IL17A*-ind/+ strain strongly supports a mechanism whereby IL-6 propagates IL-17-induced inflammation, as confirmed by the noticeable presence of IL-6R*α*-expressing monocytes and neutrophils in the affected skin \[[@B23]\].

In this setting, the inflammatory cascade starts with epidermal IL-17A expression in the absence of IL-23 overexpression; similar conditions (i.e., a high IL-17A/IL-23 ratio) have been described as characteristic of bioptic samples of human PP compared to conventional PV (whereby IL-17A levels appear to follow those of IL-23). The persistent expression of IL-17A in basal keratinocytes seems to induce target cell to secrete significant amounts of IL-6, resulting in high levels of circulating IL-6 and sIL-6/IL-6R heterodimers \[[@B23]\]; increased levels of local and systemic IL-6 influence IL-6R-alpha+ neutrophils and monocytes activity, leading to aberrant chemotaxis into lesional skin and formation of intraepidermal neutrophil microabscesses \[[@B23]\].

Importantly, administration of anti-IL-6 neutralizing antibody in K14-*IL17A*-ind/+ mice is sufficient to reduce and prevent the extent of leukocyte infiltration, leading to a sizeable decrease in cutaneous accumulation of myeloperoxidase+ CD11b+ cells, intraepidermal neutrophil microabscesses formation, and epidermal changes \[[@B23]\]. Hence, IL-6 seems to play a key role in the innate component of IL-17-driven PP-like dermatitis, and blockade of IL-6 activity may result in dramatic clinicopathological improvements despite the persistent activation of the IL-17 signaling.

Interestingly, gene expression evaluation of psoriatic plaques in the initial 48 hours after anti-TNF-alpha infliximab administration revealed significant inhibition of slan-DC-derived IL-1b, TNF-alpha, IFN-gamma, IL-12, and IL-23 but not IL-6, suggesting that direct TNF-alpha blockade is less effective in targeting IL-6 production by inflammatory dermal DCs \[[@B95]\]. If IL-6 signaling was more relevant to PP development than to PV, such data would provide an explanation to clinical evidence that efficacy rates of TNF-alpha inhibitors in PP are lower as compared to PV \[[@B14]\].

4. Conclusions {#sec4}
==============

So far, the experience with IL-6 inhibitors in psoriasis is limited, as other signaling pathways have been successfully investigated as therapeutic targets (i.e., TNF-alpha, IL-23, and IL-17) \[[@B8], [@B36], [@B38], [@B104]\]. Furthermore, paradoxical cases of biologic-induced psoriasiform dermatitis have been reported also for patients undergoing treatment with tocilizumab for RA \[[@B105], [@B106]\]. Tofacitinib and other Janus kinase inhibitors (targeting, among the others, also the IL-6R signaling pathway) are gaining significant attention as therapeutic options in psoriasis, but their efficacy in PP is still unclear \[[@B107], [@B108]\]. Only occasional patients with generalized PP, including paradoxical anti-TNF-induced cases, have been effectively treated with the anti-IL-6 agent tocilizumab \[[@B109], [@B110]\]. A larger amount of data exists with regard to the role of IL-1 antagonist anakinra in PP, especially in cases secondary to*IL36RN* mutations \[[@B24], [@B62], [@B64]\]. Nonetheless, it seems reasonable that IL-6 may play a crucial role as well as IL-1 independently from the persistent IL-36R activation in the epidermis \[[@B62]\]. If this evidence will be confirmed, agents neutralizing IL-1 and IL-6 may be effective in treating PP, similarly to juvenile idiopathic arthritis, which has been successfully treated with either anti-IL-1 agents or IL-6 inhibitors \[[@B82]\].
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![IL-6 signalling pathways. In classical signalling (red star), cells expressing membranous IL-6R are responsive to IL-6; in transsignalling (yellow star), cells lacking IL-6R are activated by IL-6/sIL-6R complexes (sIL-6R is generated by proteolytic shedding from IL-6R via ADAM10 and ADAM17 or by mRNA alternative splicing). Cellular events initiated by IL-6/IL-6R activity include activation of JAK, MEKs-ERKs, and PI3K/Akt kinases, resulting in changes in nuclear gene expression. IL-6: interleukin 6; sIL-6R: soluble interleukin 6 receptor.](JIR2014-964069.001){#fig1}

![IL-17/IL-6 axis in the pathogenesis of pustular psoriasis. Both innate (gamma/delta T cells, neutrophils, and macrophages) and adaptive (Th17 cells) immunities contribute to cutaneous IL-17 production. Macrophages, conventional DCs, and slan-DCs respond to IL-17 by releasing IL-6, which in turn plays a key role in neutrophils recruitment and pustules formation; additional IL-6-dependent effects include reinforcement of Th1/Th17 inflammatory cytokines production, facilitation of IL-22-mediated epidermal hyperplasia, and naive CD4+ T cells differentiation into Th17. Activated keratinocytes amplify the IL-17/IL-6 axis by producing IL-6, recruiting Th17 cells through CCL20, and inducing neutrophils chemotaxis via IL-8 and MCP-1. DCs: dendritic cells; IL: interleukin; KCs: keratinocytes; M/Ms: monocytes/macrophages; PMNs: neutrophils; Th17: T helper 17 cells.](JIR2014-964069.002){#fig2}
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